Similarly, ChIP-seq experiments showed no binding of GRHL2 to the Zeb1 or Zeb2 promoters in kidney, placenta, ovarian cancer or lung epithelial cells (Aue et al., 2015; Chung et al., 2016; Gao et al., 2013; Walentin et al., 2015). Here, GRHL2 is linked to ovarian carcinoma.